Schrödinger is excited to be participating in the AI in Drug Discovery conference taking place on March 11th – 12th in London, United Kingdom. Join us for a presentation by Karl Leswing, Executive Director at Schrödinger, titled “Latest advancements in machine learning-enhanced in silico design: Impact on a pipeline of drug discovery programs”. Stop by our booth to speak with Schrödinger scientists.
Speaker: Karl Leswing, Executive Director, Machine Learning, Schrödinger
- Using active learning with FEP+ for large-scale in silico fragment screens in hit discovery
- Applying de novo design workflows for intelligent molecular core design
- Leveraging experimental data for enhancing ADMET profiles in lead optimization using an interactive ML dashboard